News

Chugai Pharmaceutical Co., Ltd. and NTT DATA Corporation have conducted a demonstration test of a solution for improving the efficiency of clinical trial-related document preparation using AI technology from January to June, 2020. Clinical trial operations require the creation of...

Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the coronavirus that causes COVID-19. Enzyme linked...

Vibalogics, a global contract development and manufacturing organization (CDMO) that specializes in the production of virotherapy products, has announced the appointment of Tom Hochuli as Chief Executive Officer as the company accelerates its U.S. expansion and global growth strategy. Bringing...

Intravacc, a global provider of translational research and development of viral and bacterial vaccines, has been awarded a contract with base and options that may total $9.4 million from the U.S. National Institute of Allergy and Infectious Diseases (NIAID),...

Cipla Health Ltd., a leading consumer healthcare brand, has forayed into the antifungal product category with the introduction of Clocip, to offer a hardworking skin infection solution for hardworking people enabling them to continue work without any discomfort. Available in...

Roche announced that the United States (US) FDA has approved Gavreto™ (pralsetinib) for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. This indication was...

Merck, known as MSD outside the United States and Canada, has announced the results from two pivotal phase 3 trials (COUGH-1 and COUGH-2) evaluating the efficacy and safety of gefapixant (MK-7264), an investigational, orally administered, selective P2X3 receptor antagonist,...